Suppr超能文献

严重视网膜营养不良早期发病的基因治疗前景:使用特异性靶向视网膜色素上皮的腺相关病毒血清型4载体恢复RPE65 Briard犬的视力。

Gene therapeutic prospects in early onset of severe retinal dystrophy: restoration of vision in RPE65 Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium.

作者信息

Rolling F, Le Meur Guylène, Stieger Knut, Smith Alexander J, Weber Michel, Deschamps Jack Yves, Nivard Delphine, Mendes-Madeira Alexandra, Provost Nathalie, Péréon Yann, Cherel Yan, Ali Robin R, Hamel Christian, Moullier Philippe, Rolling Fabienne

机构信息

Université de Nantes.

出版信息

Bull Mem Acad R Med Belg. 2006;161(10-12):497-508; discussion 508-9.

Abstract

Previous studies have tested gene replacement therapy in RPE65 deficient dogs using recombinant adeno-associated virus 2/2 (rAAV2/2), -2/1 or -2/5 mediated delivery of the RPE65 gene. They all documented restoration of dark- and light-adapted ERG responses and improved psychophysical outcomes. Use of a specific RPE65 promoter and a rAAV vector that targets transgene expression specifically to the retinal pigmented epithelium (RPE) may, however, provide a safer setting for the long-term therapeutic expression of RPE65. Subretinal injection of rAAV2 pseudotyped with serotype 4 (rAAV2/4) specifically targets the RPE. The purpose of our study was to evaluate a rAAV2/4 vector carrying a human RPE65cDNA driven by a human RPE65 promoter, for the ability to restore vision in RPE65-/- purebred Briard dogs. Recombinant rAAV2/4 and rAAV2/2 vectors containing similar human RPE65 promoter and cDNA cassettes were generated and administered subretinally in 8 affected dogs, ages 8 to 30 months (n = 6 with rAAV2/4, n = 2 with rAAV2/2). Although fluorescein angiography and OCT examinations displayed retinal abnormalities in treated retinas, electrophysiological analysis demonstrated that restoration of rod and cone photoreceptor function started as soon as 15 days post-injection, reaching maximal function at 3 months post-injection, and remaining stable thereafter in all animals treated at 8 to 11 months of age. As assessed by the ability of these animals to avoid obstacles in both dim and normal light, functional vision was restored in the treated eye, while the untreated contralateral eye served as an internal control. The dog treated at a later age (30 months) did not recover retinal function or vision, suggesting that there might be a therapeutic window for the successful treatment of RPE65 -/- dogs by gene replacement therapy.

摘要

以往的研究使用重组腺相关病毒2/2(rAAV2/2)、-2/1或-2/5介导递送RPE65基因,在RPE65缺陷犬中测试了基因替代疗法。这些研究均记录了暗适应和明适应视网膜电图(ERG)反应的恢复以及心理物理学结果的改善。然而,使用特定的RPE65启动子和能将转基因表达特异性靶向视网膜色素上皮(RPE)的rAAV载体,可能为RPE65的长期治疗性表达提供更安全的环境。用血清型4假型化的rAAV2(rAAV2/4)进行视网膜下注射可特异性靶向RPE。我们研究的目的是评估一种携带由人RPE65启动子驱动的人RPE65 cDNA的rAAV2/4载体,恢复RPE65基因敲除(RPE65-/-)纯种布里牧犬视力的能力。构建了含有相似人RPE65启动子和cDNA盒的重组rAAV2/4和rAAV2/2载体,并将其视网膜下注射到8只8至30月龄的患病犬体内(6只注射rAAV2/4,2只注射rAAV2/2)。尽管荧光素血管造影和光学相干断层扫描(OCT)检查显示治疗后的视网膜存在异常,但电生理分析表明,注射后15天杆状和锥状光感受器功能就开始恢复,在注射后3个月达到最大功能,此后在所有8至11月龄接受治疗的动物中保持稳定。通过这些动物在暗光和正常光线下避开障碍物的能力评估,治疗眼的功能性视力得到恢复,而未治疗的对侧眼作为内部对照。在较晚年龄(30月龄)接受治疗的犬未恢复视网膜功能或视力,这表明基因替代疗法成功治疗RPE65-/-犬可能存在一个治疗窗口期。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验